Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS

Part of paid clinical trials in La Jolla, California.

Sponsor
argenx
Study ID
NCT05918978
Phase
PHASE2
Status
Terminated

Conditions

  • Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Efgartigimod — DRUG
    Participants will receive efgartigimod IV 10 mg/kg open label, respectively.

Study Details

The OLE study aims to investigate the safety, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod in participants with post-COVID-19 postural orthostatic.

Key Dates

Start date
Jun 20, 2023
Status verified
Oct 2025
Primary completion
Aug 15, 2024
Completion
Aug 15, 2024

Study Design

Enrollment
33 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Efgartigimod
    Receive efgartigimod IV 10mg/kg infusions during a treatment period of 48 weeks

Primary Outcome Measure

Number of Participants With TEAEs, TESAEs and TEAESIs [ Time Frame: From the first dose of study drug (Day 1) up to 60 days post last dose of study drug, up to 383 days ]

Locations (9)

FacilityCityStateZIPSite coordinators
UC Sand Diego Sulpizio Cardiovascular CenterLa JollaCalifornia92037-
Standford Movement Disorder CenterPalo AltoCalifornia94304-
North Shore University HealthSystemGlenviewIllinois60026-
Johns Hopkins UniversityBaltimoreMaryland21205-
Brigham and Women's HospitalBostonMassachusetts02115-
University Hospitals, Neurology Clinical TrialsClevelandOhio44106-
Apex Trials GroupFort WorthTexas76104-
Pioneer Clinical ResearchRosharonTexas77583-
Metrodora InstituteWest Valley CityUtah84119-

Find similar trials in La Jolla, CA